[go: up one dir, main page]

HUP9801700A2 - Monomer inzulin analóg tartalmú készítmények - Google Patents

Monomer inzulin analóg tartalmú készítmények

Info

Publication number
HUP9801700A2
HUP9801700A2 HU9801700A HUP9801700A HUP9801700A2 HU P9801700 A2 HUP9801700 A2 HU P9801700A2 HU 9801700 A HU9801700 A HU 9801700A HU P9801700 A HUP9801700 A HU P9801700A HU P9801700 A2 HUP9801700 A2 HU P9801700A2
Authority
HU
Hungary
Prior art keywords
approximately
insulin analog
suspension
monomeric insulin
analog formulations
Prior art date
Application number
HU9801700A
Other languages
English (en)
Inventor
Michael R. De Felippis
Bruce H. Frank
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP9801700A2 publication Critical patent/HUP9801700A2/hu
Publication of HUP9801700A3 publication Critical patent/HUP9801700A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya parenterális gyógyszerkészítmény, amely hősszúhatóanyag-kibőcsátású és steril vizes szűszpenziót tartalmaz, amelyszűszpenzió körülbelül 20 U/ml - körülbelül 500 U/ml analógőt,körülbelül 5 mg/ml - körülbelül 10 mg/ml nátriűm-klőridőt, körülbelül0,2 - körülbelül 2,0 mg/ml fiziőlógiailag elfőgadható pűffert,körülbelül 0,04 mg/ml - körülbelül 20,0 mg/ml cinkiőnt ésfiziőlógiailag elfőgadható tartósítóanyagőt tartalmaz, és pH-értékekörülbelül 6,5 - körülbelül 7,8 érték között úgy, hőgy az analógkisebb mint 5%-a van őldőtt állapőtban a szűszpenzióban. A találmányszerinti készítményt gyógyszerészetben alkalmazzák. ŕ
HU9801700A 1995-03-31 1996-03-28 Monomeric insulin analog formulations HUP9801700A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41488095A 1995-03-31 1995-03-31

Publications (2)

Publication Number Publication Date
HUP9801700A2 true HUP9801700A2 (hu) 1998-11-30
HUP9801700A3 HUP9801700A3 (en) 1998-12-28

Family

ID=23643384

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801700A HUP9801700A3 (en) 1995-03-31 1996-03-28 Monomeric insulin analog formulations

Country Status (23)

Country Link
US (1) US5952297A (hu)
EP (1) EP0735048A1 (hu)
JP (1) JPH11502856A (hu)
KR (1) KR19980703425A (hu)
CN (1) CN1185114A (hu)
AR (1) AR002976A1 (hu)
AU (1) AU720300B2 (hu)
BR (1) BR9607935A (hu)
CA (1) CA2216516A1 (hu)
CO (1) CO4700482A1 (hu)
CZ (1) CZ305297A3 (hu)
EA (1) EA000970B1 (hu)
HU (1) HUP9801700A3 (hu)
IL (1) IL117696A (hu)
MX (1) MX9707428A (hu)
NO (1) NO974498L (hu)
NZ (1) NZ305719A (hu)
PE (1) PE38797A1 (hu)
PL (1) PL322626A1 (hu)
TR (1) TR199701078T1 (hu)
WO (1) WO1996030040A1 (hu)
YU (1) YU18596A (hu)
ZA (1) ZA962502B (hu)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
DK1283051T3 (da) * 1997-06-13 2006-10-16 Lilly Co Eli Stabile insulinformuleringer
US20010053761A1 (en) * 1998-01-08 2001-12-20 Dimarchi Richard Dennis Method for administering aspb28-human insulin
AU2827199A (en) * 1998-03-24 1999-10-18 Klavs Holger Jorgensen Novel preparation of protracted acting human insulin
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
CN1125081C (zh) 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
WO2001052937A1 (en) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
MXPA03007042A (es) * 2001-02-09 2004-05-24 Genentech Inc Cristalizacion de igf-1.
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
WO2003105768A2 (en) 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US7683029B2 (en) * 2003-05-07 2010-03-23 Philip Morris Usa Inc. Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
PL2626368T3 (pl) 2004-07-19 2017-06-30 Biocon Limited Koniugaty insulina-oligomer, ich formulacje i zastosowania
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
DK2203181T3 (en) 2007-10-16 2018-05-28 Biocon Ltd An orally administrable solid composition and a method thereof
CA2708762A1 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
KR20100111682A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
LT3228320T (lt) 2008-10-17 2020-03-10 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
NZ594248A (en) 2009-01-28 2015-03-27 Smartcells Inc Conjugate based systems for controlled drug delivery
CA2750252A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
RU2011137413A (ru) 2009-02-12 2013-03-20 Проекто Де Биомедисина Сима, С.Л. Применение кардиотрофина-1 для лечения метаболических заболеваний
US8623345B2 (en) 2009-03-20 2014-01-07 Smartcells Terminally-functionalized conjugates and uses thereof
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
EP2432531B1 (de) 2009-05-18 2019-03-06 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
KR101772372B1 (ko) 2009-11-13 2017-08-29 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
PE20121362A1 (es) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
EP2504051B1 (en) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
NZ599295A (en) 2009-11-25 2014-06-27 Boehringer Ingelheim Int Nebulizer
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
US9670162B2 (en) 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
MX369511B (es) 2013-04-03 2019-11-11 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada.
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
EP3077414B1 (en) 2013-12-04 2020-06-17 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP3139979B1 (en) 2014-05-07 2023-07-05 Boehringer Ingelheim International GmbH Unit, nebulizer and method
DK3139984T3 (da) 2014-05-07 2021-07-19 Boehringer Ingelheim Int Forstøver
BR112016023932B1 (pt) 2014-05-07 2022-11-29 Boehringer Ingelheim International Gmbh Nebulizador
US10258573B2 (en) 2014-07-08 2019-04-16 Amphastar Pharmaceuticals, Inc. Micronized insulin and micronized insulin analogues prepared under acidic conditions, and methods of manufacturing the same under acidic conditions
US10124040B2 (en) 2014-08-26 2018-11-13 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10322168B2 (en) * 2016-01-07 2019-06-18 Amphastar Pharmaceuticals, Inc. High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
AU2021247169A1 (en) 2020-03-31 2022-10-20 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
US20240374735A1 (en) 2020-11-19 2024-11-14 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
US12139502B2 (en) 2022-05-18 2024-11-12 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2882202A (en) * 1950-04-05 1959-04-14 Novo Terapeutisk Labor As Insulin crystal preparations and methods of producing them
US2648622A (en) * 1950-11-29 1953-08-11 Research Corp Purifying insulin by seeding with unclumped fibrils of insulin
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) * 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
AT304760B (de) * 1969-08-08 1973-01-25 Novo Terapeutisk Labor As Verfahren zur Reinigung von Insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
AU711428B2 (en) * 1994-06-16 1999-10-14 Eli Lilly And Company Monomeric insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
NZ305719A (en) 1998-09-24
EA000970B1 (ru) 2000-08-28
CO4700482A1 (es) 1998-12-29
WO1996030040A1 (en) 1996-10-03
YU18596A (sh) 1998-07-10
NO974498D0 (no) 1997-09-29
AU5381296A (en) 1996-10-16
IL117696A (en) 2000-01-31
TR199701078T1 (xx) 1998-01-21
CZ305297A3 (cs) 1998-02-18
PE38797A1 (es) 1997-10-04
AU720300B2 (en) 2000-05-25
KR19980703425A (ko) 1998-11-05
BR9607935A (pt) 1998-06-02
JPH11502856A (ja) 1999-03-09
MX9707428A (es) 1997-12-31
PL322626A1 (en) 1998-02-02
EP0735048A1 (en) 1996-10-02
NO974498L (no) 1997-10-08
AR002976A1 (es) 1998-05-27
IL117696A0 (en) 1996-07-23
CN1185114A (zh) 1998-06-17
ZA962502B (en) 1997-09-29
US5952297A (en) 1999-09-14
HUP9801700A3 (en) 1998-12-28
CA2216516A1 (en) 1996-10-03
EA199700285A1 (ru) 1998-02-26

Similar Documents

Publication Publication Date Title
HUP9801700A2 (hu) Monomer inzulin analóg tartalmú készítmények
EP1234586A3 (en) Hepatoselective pharmaceutical actives
HUP9603237A2 (hu) (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzizotiazol-2-il)-butil]-amino-metil}-kromán kristályos hidrokloridja, eljárás előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0100284A2 (hu) Aktivált protein C készítmények
GR900100481A (el) Μέ?οδος παρακευής υδατικού αιωρήματος για ουσιαστικά αδιάλυτους στο νερό ενεργούς παράγοντες.
MX9504034A (es) Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas.
HUP0000589A2 (hu) Vizes peptid készítmények
EP1243269A3 (en) Opioid formulations having extended controlled release
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
CA2106172A1 (en) Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention
NO20022264D0 (no) Farmasöytisk blanding inneholdende tolterodin, samt anvendelse derav
HUP0000299A1 (hu) Késleltetett hatóanyag-leadású gyógyszerkészítmények
AU7451198A (en) Solid pharmaceutical preparation
CA2058835A1 (en) Stable pharmaceutical composition and method for its production
HUP0101545A1 (hu) Peptideket időben elnyújtva kibocsátó gyógyászati készítmények és eljárás az előállításukra
CA2329005A1 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
HUP9802339A2 (hu) Darifenacint tartalmazó gyógyászati készítmények
CA2258095A1 (en) Tetrahydrolipstatin containing compositions
IE892594L (en) Pharmaceutical formulation for the treatment of diabetes¹mellitus
CA2164776A1 (en) Pharmaceutical, orally applicable composition
PL367464A1 (en) Pharmaceutical composition comprising lumiracoxib
HUP9801227A2 (hu) Monoamin-oxidáz B inhibitorokból álló gyógyászati készítmények és alkalmazásuk
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
CA2255064A1 (en) Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
BG103306A (en) Liquid allendronate compositions